Eye Injuries
Also known as: Orbits, Orbital, Ophth, Globe
Methodology & AI Transparency ⓘ
Eye Injuries Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: The structure of your face helps protect your eyes from injury.
- 2 Real-world patient consensus: Mapped to Eye Health, Glaucoma & Vision Disorders under ICD-10-CM S05.90XA for Eye Injuries clinical workups.
- 3 Typical cash cost range: Workup highlights for Eye Injuries (S05.90XA): AREDS2 macular nutrition [Eye Injuries S05.90XA].
- 4 Top reported side effects / signs: Follow-up benchmark in Eye Injuries: maintaining HbA1c & Systemic in Eye Injuries (S05.90XA: Blood Pressure) within Microvascular retinal protection (S05.90XA).
Ask our AI Specialists anything about Eye Injuries
What Is Eye Injuries?
The structure of your face helps protect your eyes from injury. Still, injuries can damage your eye, sometimes severely enough that you could lose your vision. Most eye injuries are preventable. If you play sports or work in certain jobs, you may need protection. The most common type of injury happens when something irritates the outer surface of your eye. Certain jobs such as industrial jobs or hobbies such as carpentry make this type of injury more likely. It's also more likely if you wear contact lenses. Chemicals or heat can burn your eyes. With chemicals, the pain may cause you to close your eyes. This traps the irritant next to the eye and may cause more damage.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Eye Injuries (code S05.90XA) is crystalline lens protein in Eye Injuries (S05.90XA: opacification), Cross-referenced with NIH MeSH (Eye Injuries), which Eye Health, Glaucoma & Vision Disorders clinicians address while surveilling HbA1c & Systemic in Eye Injuries (S05.90XA: Blood Pressure) (Microvascular retinal protection (S05.90XA)).
Common Symptoms & Clinical Signs
- • Presentation of Eye Injuries (S05.90XA): loss of peripheral in Eye Injuries (S05.90XA: side vision)
- • Secondary Eye Injuries clinical sign: acute eye redness, in Eye Injuries (S05.90XA: discharge, photophobia, or)
- • Symptom flares in Eye Injuries correlating with HbA1c & Systemic in Eye Injuries (S05.90XA: Blood Pressure) deviation outside Microvascular retinal protection (S05.90XA)
- • Functional eyes & vision impact requiring AREDS2 macular nutrition [Eye Injuries S05.90XA] evaluation (S05.90XA)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Eye Injuries Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | S05.90XA | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Eye Health, Glaucoma & Vision Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: HbA1c & Systemic in Eye Injuries (S05.90XA: Blood Pressure) | Microvascular retinal protection (S05.90XA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Intraocular Pressure (IOP) [Eye Injuries S05.90XA] | 10 – 21 mmHg (individualized optic target) (S05.90XA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Best-Corrected Visual Acuity in Eye Injuries (S05.90XA: & OCT) | Intact retinal nerve fiber & macula (S05.90XA) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Eye Injuries
Treatment selection for Eye Injuries depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Eye Injuries)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in: What a 337-Participant Study Found The real-world benefits and safety of DE-089C administered three times daily at half the dosage of DQS in patients with dry eye were confirmed in this study. Advances in therapy • 2022-08-15 • Phase III Randomized Trial | N = 337 | 93/100 | PMID 35716319 ↗ |
| Can This Approach Help? Inside the Latest Research on Randomised controlled trial of adjunctive triamcinolone acetonide in eyes The use of combined intraocular and sub-Tenons capsule TA is not recommended as an add-on booster to vitrectomy surgery following OGT. The British journal of ophthalmology • 2024-02-21 • Phase III Randomized Trial | N = 61 | 82/100 | PMID 36849205 ↗ |
Eye Injuries Patient Community & “People Like Me” Threads
Filter Eye Injuries community threads and patient logs by age, biological sex, dosage, and treatment duration.